Berberine Binds Rxr Alpha To Suppress Beta-Catenin Signaling In Colon Cancer Cells
H. Ruan,Y. Y. Zhan,J. Hou,B. Xu,B. Chen,Y. Tian,D. Wu,Y. Zhao,Y. Zhang,X. Chen,P. Mi,L. Zhang,S. Zhang,X. Wang,H. Cao,W. Zhang,H. Wang,H. Li,Y. Su,X. K. Zhang,T. Hu
DOI: https://doi.org/10.1038/onc.2017.296
IF: 8.756
2017-01-01
Oncogene
Abstract:Berberine, an isoquinoline alkaloid, is a traditional oriental medicine used to treat diarrhea and gastroenteritis. Recently, we reported that it could inhibit the growth of intestinal polyp in animals and in patients with the familial adenomatous polyposis by downregulating beta-catenin signaling. However, the intracellular target mediating the effects of berberine remains elusive. Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXR alpha), where berberine concomitantly binding to and synergistically activating RXR alpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXR alpha. Berberine binding promotes RXR alpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells. Furthermore, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXR alpha-dependent manner. Together, our study not only identifies RXRa as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXR alpha, which provide new strategies for the design of new RXR alpha-based antitumor agents and drug combinations.